Neurooncología.pósters

 

Envíos recientes

  • Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial 
    Olaf Witt, Sameer Farouk Sait; Diez, Blanca; Cardoso, Agustín; Reardon, David A.; Welsh, Liam; Shih, Kent C.; Baldini, Capucine; Massard, Christophe; Loriot, Yohann; Pant, Shubham; Sweiti, Hussein; Thomas, Shibu; Hammond, Constance; Najmi, Saltanat; Triantos, Spyros; Crow, Lauren; Geoerger, Birgit (American Society of Clinical Oncology, 2024-06)
    Background: Erdafitinib is an oral selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved in the US for adult patients (pts) with locally advanced or metastatic urothelial carcinoma with ...
  • Clinical efficacy of a next-generation sequencing (NGS) and immunohistochemistry (IHC) panel in patients with advanced cancer in Argentina. 
    Cantarella, Florencia; Mendoza Bertelli, Andrea; Girotti, Romina; Marino, Ana Clara; Brest, Esteban; Dibarbora, Delfina; Mahmoud, Yamil; Veigas, Florencia; Enrico, Diego Hernan; Tsou, Florencia; Lacava, Juan A.; Piazzoni, Luciano; Riso, Aldo Alejandro; Martinengo, Gastón L.; Rodriguez, Andrés; Beguelin, Zenon; Cerrato, Sebastián; Jerez, Ignacio; Salanova, Rubén (American Society of Clinical Oncology, 2024-05-29)
    Background: The analysis of somatic genomic alterations, evaluation of DNA mismatch repair (MMR) proteins, and examination of PD-L1 expression in tumor biopsies are crucial for prognosis and informed therapeutic decisions. ...
  • 6P Extraosseous central nervous system Ewing sarcoma: A single-center retrospective case series 
    Yorio, Florencia; Arakaki, Naomi; Alessandro, Lucas; Palomar, Nicolás; Diez, Blanca; Muggeri, Alejandro (ESMO, 2024-03)
    Background Ewing Sarcoma (ES) tumors are malignant tumors mainly affecting pediatric patients. Extra-osseous primary sites are infrequent, being central nervous system (CNS)-ES extremely rare. Diverse differential ...